Cargando…

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients

INTRODUCTION: Alzheimer’s disease (AD) is the most common neurodegenerative form of dementia. Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs) and memantine, have been available in the USA since 2000. Over the past decade, few studies have analyze...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bent-Ennakhil, Nawal, Coste, Florence, Xie, Lin, Aigbogun, Myrlene Sanon, Wang, Yuexi, Kariburyo, Furaha, Hartry, Ann, Baser, Onur, Neumann, Peter, Fillit, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447560/ https://www.ncbi.nlm.nih.gov/pubmed/28508250 http://dx.doi.org/10.1007/s40120-017-0067-7

Ejemplares similares

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
por: Aigbogun, Myrlene Sanon, et al.
Publicado: (2019)

Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia
por: Halpern, Rachel, et al.
Publicado: (2018)

Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review
por: Aigbogun, Myrlene Sanon, et al.
Publicado: (2020)

Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?
por: Fox, Chris, et al.
Publicado: (2006)

Assessing the Economic Burden and Health Care Utilizations of U.S. Veteran Patients with Schizophrenia
por: Xie, Lin, et al.
Publicado: (2013)

Severity of memory impairment in the elderly: Association with health care resource use and functional limitations in the United States
por: Aigbogun, Myrlene Sanon, et al.
Publicado: (2017)

Institutionalization risk and costs associated with agitation in Alzheimer's disease
por: Cloutier, Martin, et al.
Publicado: (2019)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia
por: Rubino, Annalisa, et al.
Publicado: (2020)

Radiographic Imaging in Autosomal Dominant Polycystic Kidney Disease: A Claims Analysis
por: Sanon Aigbogun, Myrlene, et al.
Publicado: (2021)

Development of a Risk Index for Serious Prescription Opioid‐Induced Respiratory Depression or Overdose in Veterans’ Health Administration Patients
por: Zedler, Barbara, et al.
Publicado: (2015)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System
por: Jones, Eddie, et al.
Publicado: (2021)

The societal economic burden of autosomal dominant polycystic kidney disease in the United States
por: Cloutier, Martin, et al.
Publicado: (2020)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
por: Hartry, Ann, et al.
Publicado: (2018)

Impact of agitation in long‐term care residents with dementia in the United States
por: Fillit, Howard, et al.
Publicado: (2021)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

Disconnect in Assessments of Autosomal Dominant Polycystic Kidney Disease Burden Between Patients and Physicians: A Survey Study
por: Sanon Aigbogun, Myrlene, et al.
Publicado: (2021)

Functional performance in patients with COPD: association with treatment regimen, GOLD group, lung function, and symptom burden in a cross-sectional study
por: Ding, Bo, et al.
Publicado: (2018)

Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study
por: Kariburyo, Furaha, et al.
Publicado: (2018)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
por: Dou, Kai-Xin, et al.
Publicado: (2018)

Predictors and Outcomes of Hospitalization for Influenza: Real-World Evidence from the United States Medicare Population
por: Bolge, Susan C., et al.
Publicado: (2020)

Burden of Pneumonia Among Hospitalized Patients with Influenza: Real-World Evidence from a US Managed Care Population
por: Bolge, Susan C., et al.
Publicado: (2021)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil and Camicioli
por: Tariot, Pierre N., et al.
Publicado: (2014)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population
por: Lee, Seina, et al.
Publicado: (2018)

A Real-World Analysis of Patient Characteristics and Predictors of Hospitalization Among US Medicare Beneficiaries with Respiratory Syncytial Virus Infection
por: Wyffels, Veronique, et al.
Publicado: (2020)

Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers
por: Kariburyo, M. Furaha, et al.
Publicado: (2017)

Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
por: Ogbomo, Adesuwa, et al.
Publicado: (2021)

The Symptoms Targeted for Monitoring in a Web-Based Tracking Tool by Caregivers of People With Dementia and Agitation: Cross-Sectional Study
por: Rockwood, Kenneth, et al.
Publicado: (2019)

Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study
por: Weisshof, Roni, et al.
Publicado: (2023)

Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
por: Zhang, Yunpeng, et al.
Publicado: (2019)

Pharmacodynamics of Memantine: An Update
por: Rammes, G, et al.
Publicado: (2008)

Association of newly diagnosed type 1 diabetes and autoimmune pancreatitis
por: Ennazk, Laila, et al.
Publicado: (2016)

Patient and Care Partner Burden in CKD Patients With and Without Anemia: A US-Based Survey
por: Michalopoulos, Steven N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uiv2nq7bqs8ocod4d8kgrhsbca